JP2015508156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508156A5 JP2015508156A5 JP2014554887A JP2014554887A JP2015508156A5 JP 2015508156 A5 JP2015508156 A5 JP 2015508156A5 JP 2014554887 A JP2014554887 A JP 2014554887A JP 2014554887 A JP2014554887 A JP 2014554887A JP 2015508156 A5 JP2015508156 A5 JP 2015508156A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cancer
- biomarkers
- patient
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 239000000090 biomarker Substances 0.000 claims description 38
- 244000309459 oncolytic virus Species 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 18
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- -1 butane-1,4-diyldimethyl Chemical group 0.000 claims description 9
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 6
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 5
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229960005386 ipilimumab Drugs 0.000 claims description 5
- 229960004942 lenalidomide Drugs 0.000 claims description 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 5
- 229960003301 nivolumab Drugs 0.000 claims description 5
- 230000000174 oncolytic effect Effects 0.000 claims description 5
- 229960002621 pembrolizumab Drugs 0.000 claims description 5
- 229950007217 tremelimumab Drugs 0.000 claims description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- 102100021906 Cyclin-O Human genes 0.000 claims description 4
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- OUUYBRCCFUEMLH-YDALLXLXSA-N [(1s)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 208000029824 high grade glioma Diseases 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 4
- 201000011614 malignant glioma Diseases 0.000 claims description 4
- 229960002514 melphalan hydrochloride Drugs 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 3
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 229950010773 pidilizumab Drugs 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- 229950005972 urelumab Drugs 0.000 claims description 3
- XNBDOMAZQQFPOD-JTQLQIEISA-N (2s)-2-[amino(2-chloroethyl)amino]-3-phenylpropanoic acid Chemical compound ClCCN(N)[C@H](C(O)=O)CC1=CC=CC=C1 XNBDOMAZQQFPOD-JTQLQIEISA-N 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000473 altretamine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 208000030173 low grade glioma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
- 229960004961 mechlorethamine Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001052 streptozocin Drugs 0.000 claims description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 2
- 229960001196 thiotepa Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 19
- 206010059282 Metastases to central nervous system Diseases 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 239000000523 sample Substances 0.000 description 20
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 102100025338 Calcium-binding tyrosine phosphorylation-regulated protein Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000935132 Homo sapiens Calcium-binding tyrosine phosphorylation-regulated protein Proteins 0.000 description 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
- 101001036675 Homo sapiens Melanoma-associated antigen B6 Proteins 0.000 description 2
- 101001128135 Homo sapiens NACHT, LRR and PYD domains-containing protein 4 Proteins 0.000 description 2
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 2
- 101000880775 Homo sapiens Protein SSX5 Proteins 0.000 description 2
- 101000964582 Homo sapiens Zinc finger protein 165 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 102100039483 Melanoma-associated antigen B6 Human genes 0.000 description 2
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 2
- 102100031898 NACHT, LRR and PYD domains-containing protein 4 Human genes 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 102100037723 Protein SSX5 Human genes 0.000 description 2
- 241000837158 Senecavirus A Species 0.000 description 2
- 102100040814 Zinc finger protein 165 Human genes 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 1
- 229940121697 CD27 agonist Drugs 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 102100027367 Cysteine-rich secretory protein 3 Human genes 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102100038652 Ferritin heavy polypeptide-like 17 Human genes 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 1
- 101000726258 Homo sapiens Cysteine-rich secretory protein 3 Proteins 0.000 description 1
- 101001031604 Homo sapiens Ferritin heavy polypeptide-like 17 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001130171 Homo sapiens L-lactate dehydrogenase C chain Proteins 0.000 description 1
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 1
- 101001005720 Homo sapiens Melanoma-associated antigen 4 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000880774 Homo sapiens Protein SSX4 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000825253 Homo sapiens Sperm protein associated with the nucleus on the X chromosome A Proteins 0.000 description 1
- 101000612981 Homo sapiens Testis-specific gene 10 protein Proteins 0.000 description 1
- 101000794200 Homo sapiens Testis-specific serine/threonine-protein kinase 6 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000772169 Homo sapiens Tubby-related protein 2 Proteins 0.000 description 1
- 101000814511 Homo sapiens X antigen family member 2 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 102100031357 L-lactate dehydrogenase C chain Human genes 0.000 description 1
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100025077 Melanoma-associated antigen 4 Human genes 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102100037727 Protein SSX4 Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100022327 Sperm protein associated with the nucleus on the X chromosome A Human genes 0.000 description 1
- 102100040873 Testis-specific gene 10 protein Human genes 0.000 description 1
- 102100030141 Testis-specific serine/threonine-protein kinase 6 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- 102100029294 Tubby-related protein 2 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 102100039492 X antigen family member 2 Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590441P | 2012-01-25 | 2012-01-25 | |
| US61/590,441 | 2012-01-25 | ||
| US201261637191P | 2012-04-23 | 2012-04-23 | |
| US61/637,191 | 2012-04-23 | ||
| PCT/US2013/023304 WO2013112942A1 (en) | 2012-01-25 | 2013-01-25 | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018211406A Division JP2019066482A (ja) | 2012-01-25 | 2018-11-09 | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015508156A JP2015508156A (ja) | 2015-03-16 |
| JP2015508156A5 true JP2015508156A5 (enExample) | 2016-03-10 |
Family
ID=47754947
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554887A Pending JP2015508156A (ja) | 2012-01-25 | 2013-01-25 | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
| JP2018211406A Pending JP2019066482A (ja) | 2012-01-25 | 2018-11-09 | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
| JP2021035972A Pending JP2021103174A (ja) | 2012-01-25 | 2021-03-08 | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018211406A Pending JP2019066482A (ja) | 2012-01-25 | 2018-11-09 | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
| JP2021035972A Pending JP2021103174A (ja) | 2012-01-25 | 2021-03-08 | バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10238698B2 (enExample) |
| EP (2) | EP2806883B1 (enExample) |
| JP (3) | JP2015508156A (enExample) |
| KR (1) | KR102081567B1 (enExample) |
| CN (1) | CN104427992B (enExample) |
| AU (2) | AU2013211871B2 (enExample) |
| BR (1) | BR112014018331A8 (enExample) |
| CA (1) | CA2862390A1 (enExample) |
| DK (1) | DK2806883T3 (enExample) |
| SG (3) | SG11201404313YA (enExample) |
| WO (1) | WO2013112942A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008007056A (es) | 2005-12-02 | 2008-11-12 | Sinai School Medicine | Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos. |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010091262A1 (en) | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
| EP4663241A3 (en) | 2010-10-08 | 2026-03-25 | Mesoblast International Sàrl | Enhanced msc preparations |
| US11155599B2 (en) | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| WO2013131050A1 (en) * | 2012-03-02 | 2013-09-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for differential treatment of cancer |
| US20150118244A1 (en) * | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
| FI3381942T4 (fi) * | 2012-08-30 | 2025-12-16 | Amgen Inc | Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen |
| KR102222157B1 (ko) | 2013-03-14 | 2021-03-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 뉴캐슬병 바이러스 및 이의 용도 |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| CN104415335A (zh) * | 2013-09-02 | 2015-03-18 | 北京中康万达医药科技有限公司 | 体内个体化系统免疫治疗方法和装置 |
| KR20160137946A (ko) * | 2013-11-22 | 2016-12-02 | 디엔에이트릭스, 인코포레이티드 | 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스 |
| WO2015127501A1 (en) * | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
| EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
| US20170115291A1 (en) * | 2014-05-28 | 2017-04-27 | Dana-Farber Cancer Institute, Inc. | Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response |
| WO2016065330A1 (en) * | 2014-10-24 | 2016-04-28 | Aladar Szalay | Combination immunotherapy approach for treatment of cancer |
| WO2016149350A1 (en) * | 2015-03-17 | 2016-09-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
| AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| EP4667487A2 (en) | 2015-06-03 | 2025-12-24 | Aelan Cell Technologies, Inc. | Companion methods and kits for il-2-based therapies and mesenchymal stem cell-based therapies |
| WO2017013421A1 (en) | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| JP6452266B2 (ja) * | 2015-07-22 | 2019-01-16 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| EA201800148A1 (ru) | 2015-08-11 | 2019-01-31 | Калиди Биотерапьютикс, Инк. | Оспенная вакцина для лечения рака |
| JP2018526382A (ja) | 2015-09-04 | 2018-09-13 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 耐性癌または難治性癌の治療用バルリチニブ |
| WO2017062615A2 (en) * | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
| US10744170B2 (en) * | 2015-10-15 | 2020-08-18 | Duke University | Combination treatment |
| CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
| CN108367070B (zh) * | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| WO2017118866A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Engineered virus |
| EP3193173A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Serological autoantibodies as biomarker for colorectal cancer |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| EP4070812A1 (en) * | 2016-01-21 | 2022-10-12 | The Board of Trustees of the Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| CN105603085B (zh) * | 2016-01-29 | 2019-01-29 | 北京泱深生物信息技术有限公司 | 椎间盘退行性病变的诊治靶标 |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| MA55153A (fr) * | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| ES3041500T3 (en) * | 2016-03-10 | 2025-11-12 | Cg Oncology Inc | Methods of treating solid tumors by combination therapy |
| WO2017176289A1 (en) * | 2016-04-08 | 2017-10-12 | Celgene Corporation | Uses of lenalidomide and car t-cells |
| GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
| CN109789177A (zh) * | 2016-05-27 | 2019-05-21 | 德那翠丝有限公司 | 腺病毒和免疫调节剂组合治疗 |
| WO2017218757A1 (en) * | 2016-06-17 | 2017-12-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN109983121A (zh) | 2016-06-30 | 2019-07-05 | 昂克诺斯公司 | 治疗性多肽的假型化溶瘤病毒递送 |
| US20190185571A1 (en) * | 2016-07-28 | 2019-06-20 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
| CA3040194A1 (en) * | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
| US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CN110381997A (zh) * | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| JP2020504767A (ja) | 2016-12-21 | 2020-02-13 | メムゲン，エルエルシー | 武装した複製可能な腫瘍溶解性アデノウイルス |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EP4628895A3 (en) | 2017-01-13 | 2025-12-17 | Mayo Foundation for Medical Education and Research | Materials and methods for treating cancer |
| CN108341818A (zh) * | 2017-01-21 | 2018-07-31 | 南京华威医药科技开发有限公司 | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 |
| CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
| JP2020510444A (ja) * | 2017-02-08 | 2020-04-09 | ミトラ アールエックスディーエックス, インコーポレイテッドMitra Rxdx, Inc. | 抗がん剤の臨床成果を予測する方法 |
| US20200046696A1 (en) * | 2017-02-14 | 2020-02-13 | Celgene Corporation | Treatment of cancer with smg1-inhibitors |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| MX2019012741A (es) | 2017-04-28 | 2020-01-21 | Merck Sharp & Dohme | Biomarcadores para agentes terapeuticos contra el cancer. |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| EP3740503A1 (en) * | 2018-01-17 | 2020-11-25 | Eli Lilly and Company | Compounds and methods targeting interleukin-19 |
| CN108414660B (zh) * | 2018-03-08 | 2020-03-20 | 中国药科大学 | 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用 |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| CN110527696A (zh) * | 2018-06-13 | 2019-12-03 | 中山大学 | 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用 |
| KR102091567B1 (ko) * | 2018-06-15 | 2020-03-20 | 인하대학교 산학협력단 | 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물 |
| CN110755619A (zh) * | 2018-07-27 | 2020-02-07 | 复旦大学 | 一种人疱疹病毒裂解复制激活的宿主标志物及其用途 |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| CN108998529A (zh) * | 2018-08-30 | 2018-12-14 | 上海交通大学医学院附属上海儿童医学中心 | 肺腺癌检测试剂盒及检测tulp2基因甲基化水平的方法 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113271955A (zh) * | 2018-11-06 | 2021-08-17 | 卡利迪生物治疗有限公司 | 用于细胞介导的溶瘤病毒疗法的增强的系统 |
| TW202102207A (zh) * | 2019-03-27 | 2021-01-16 | 新加坡商新加坡保健服務集團有限公司 | 對於癌病具有治療意義的生物標記 |
| JP7608357B2 (ja) * | 2019-03-28 | 2025-01-06 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | ＶＳＶ－ＩＦＮβ－ＮＩＳ腫瘍溶解療法における薬力学マーカーとしてのＩＦＮβ |
| KR102199141B1 (ko) | 2019-05-03 | 2021-01-06 | 사회복지법인 삼성생명공익재단 | 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법 |
| MX2021013588A (es) | 2019-05-08 | 2022-02-11 | Medigene Immunotherapies Gmbh | Células t genomodificadas. |
| JP2022533480A (ja) * | 2019-05-24 | 2022-07-22 | エディフィス ヘルス，インコーポレーテッド | 癌免疫療法のためのプレシジョンメディシン法 |
| CN114423860A (zh) | 2019-08-05 | 2022-04-29 | 迈索布拉斯特国际有限公司 | 包含病毒载体的细胞组合物及治疗方法 |
| CN110687281B (zh) * | 2019-08-26 | 2023-05-23 | 中国医学科学院肿瘤医院 | Pd-l1自身抗体在肿瘤预后评估中的应用 |
| CN114630683A (zh) * | 2019-08-29 | 2022-06-14 | 拜耳诺克斯有限公司 | 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物 |
| WO2021061775A1 (en) * | 2019-09-23 | 2021-04-01 | Sillajen, Inc. | Immune assay for monitoring response to oncolytic vaccinia virus and uses thereof |
| CN111337678B (zh) * | 2020-02-21 | 2023-06-06 | 杭州凯保罗生物科技有限公司 | 与肿瘤免疫治疗效果相关的生物标志物及其应用 |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| WO2021225422A1 (ko) * | 2020-05-08 | 2021-11-11 | 주식회사 루닛 | 병리 슬라이드 이미지에 대한 면역 표현형과 연관된 정보를 제공하는 방법 및 장치 |
| WO2021225421A1 (ko) | 2020-05-08 | 2021-11-11 | 주식회사 루닛 | 면역 항암제에 대한 반응을 예측하는 방법 및 시스템 |
| EP4105943A4 (en) * | 2020-05-08 | 2024-03-20 | Lunit Inc. | Method and system for predicting reaction to immuno-oncology agent |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| CN111579788A (zh) * | 2020-05-29 | 2020-08-25 | 郑州大学 | 一种高灵敏肿瘤标志物EPHA2的Simoa试剂盒及其应用 |
| CN115996735A (zh) | 2020-08-10 | 2023-04-21 | 迈索布拉斯特国际有限公司 | 细胞组合物和治疗方法 |
| CN116322728A (zh) * | 2020-08-14 | 2023-06-23 | 上海行深生物科技有限公司 | 水疱性口炎病毒及其治疗用途 |
| CN112345755B (zh) * | 2020-09-23 | 2023-06-16 | 杭州凯保罗生物科技有限公司 | 乳腺癌的生物标志物及其应用 |
| KR102710867B1 (ko) * | 2020-12-18 | 2024-09-27 | (주)인비보텍 | Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물 |
| US20240036045A1 (en) * | 2020-12-22 | 2024-02-01 | The Brigham And Women`S Hospital, Inc. | Blood-based protein biomarker panel for early and accurate detection of cancer |
| CN114764101B (zh) * | 2021-01-25 | 2025-08-08 | 武汉大学中南医院 | 一种确定具有gbm预后价值的血液炎症标志物的方法及gbm生存率计算系统 |
| EP4444873A4 (en) * | 2021-12-06 | 2026-03-04 | Elevatebio Tech Inc | Compositions and methods of cancer therapy related to the Seneca Valley Virus (SVV) |
| JP2025536260A (ja) | 2022-10-11 | 2025-11-05 | イェール ユニバーシティー | 細胞透過性抗体の組成物および使用方法 |
| CN115948557B (zh) * | 2023-01-04 | 2025-09-02 | 陕西师范大学 | 一种nlrp2作为靶点在卵巢癌疾病诊断和/或治疗中的应用 |
| CN120835927A (zh) * | 2023-09-28 | 2025-10-24 | 复旦大学附属华山医院 | 用于治疗胶质瘤的组合物 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| EP0791050B1 (en) | 1994-11-28 | 2006-02-15 | Cell Genesys Inc. | Vectors for tissue-specific replication |
| EP0821739B1 (en) | 1995-04-17 | 2003-06-18 | The Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| JP2002514075A (ja) | 1997-03-03 | 2002-05-14 | セル ジェネシス，インコーポレイティド | 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| JP2002530085A (ja) | 1998-11-18 | 2002-09-17 | カンジ，インコーポレイテッド | 後期導入遺伝子の発現を有するウイルスベクター |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US6824771B1 (en) | 1999-05-12 | 2004-11-30 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| ATE371031T1 (de) | 1999-06-08 | 2007-09-15 | Uab Research Foundation | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| CA2386626A1 (en) | 1999-10-15 | 2001-04-26 | Richard Murphy | Targeted vectors |
| US6740525B2 (en) | 2000-02-09 | 2004-05-25 | Genvec, Inc. | Adenoviral capsid containing chimeric protein IX |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030211477A1 (en) | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| US7736644B2 (en) | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20070134202A1 (en) * | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| CA2563103C (en) * | 2004-03-31 | 2015-02-17 | Tomoki Todo | Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer |
| CN101098877A (zh) | 2004-07-13 | 2008-01-02 | 不列颠哥伦比亚大学 | 吲哚胺-2,3-双加氧酶(ido)抑制剂 |
| ES2605380T3 (es) | 2005-05-06 | 2017-03-14 | Providence Health & Services - Oregon | Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso |
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| AU2006287052B2 (en) * | 2005-08-31 | 2009-03-12 | Oncolytics Biotech Inc. | Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms |
| US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
| WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| JP2012513209A (ja) | 2008-12-22 | 2012-06-14 | オンコス セラピュティックス オサケ ユキチュア | 腫瘍溶解アデノウイルスベクター並びに前記に関連する方法および使用 |
| CN101607985B (zh) | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| EP4311863A3 (en) | 2009-05-15 | 2024-04-10 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction |
| US20100297072A1 (en) * | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2266588A1 (en) * | 2009-06-04 | 2010-12-29 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Method for cancer therapy based on co-administration of a parovirus and a cytokine |
| CN104826106B (zh) * | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2407177A1 (en) | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
| EP2383577A1 (en) | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US11155599B2 (en) | 2012-02-02 | 2021-10-26 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
| EP3010519B1 (en) | 2013-06-18 | 2021-04-07 | Dnatrix Inc. | Oncolytic adenovirus for use in a treatment of brain cancer |
-
2013
- 2013-01-25 DK DK13706770.8T patent/DK2806883T3/da active
- 2013-01-25 JP JP2014554887A patent/JP2015508156A/ja active Pending
- 2013-01-25 KR KR1020147023448A patent/KR102081567B1/ko active Active
- 2013-01-25 CN CN201380010639.1A patent/CN104427992B/zh active Active
- 2013-01-25 WO PCT/US2013/023304 patent/WO2013112942A1/en not_active Ceased
- 2013-01-25 SG SG11201404313YA patent/SG11201404313YA/en unknown
- 2013-01-25 SG SG10201913784YA patent/SG10201913784YA/en unknown
- 2013-01-25 SG SG10201604654RA patent/SG10201604654RA/en unknown
- 2013-01-25 EP EP13706770.8A patent/EP2806883B1/en active Active
- 2013-01-25 US US14/374,619 patent/US10238698B2/en active Active
- 2013-01-25 AU AU2013211871A patent/AU2013211871B2/en not_active Ceased
- 2013-01-25 EP EP19170696.9A patent/EP3578198A1/en not_active Withdrawn
- 2013-01-25 CA CA2862390A patent/CA2862390A1/en not_active Abandoned
- 2013-01-25 BR BR112014018331A patent/BR112014018331A8/pt not_active Application Discontinuation
-
2018
- 2018-03-13 AU AU2018201776A patent/AU2018201776A1/en not_active Abandoned
- 2018-11-09 JP JP2018211406A patent/JP2019066482A/ja active Pending
-
2019
- 2019-03-05 US US16/293,624 patent/US20190269744A1/en not_active Abandoned
-
2020
- 2020-06-30 US US16/917,170 patent/US11065285B2/en active Active
-
2021
- 2021-03-08 JP JP2021035972A patent/JP2021103174A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agache et al. | Advances and highlights in asthma in 2021 | |
| Toor et al. | T‐cell responses and therapies against SARS‐CoV‐2 infection | |
| Zeng et al. | Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas | |
| Wang et al. | Therapeutic strategies to remodel immunologically cold tumors | |
| KR102081567B1 (ko) | 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법 | |
| JP6912199B2 (ja) | 免疫腫瘍溶解療法 | |
| US20240374597A1 (en) | Methods and compositions for treatment of kras mutant cancer | |
| JP2021527694A5 (enExample) | ||
| AU2017241837A1 (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| JP2020517737A (ja) | 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法 | |
| Li et al. | Glycididazole sodium combined with radiochemotherapy for locally advanced nasopharyngeal carcinoma | |
| US20150374767A1 (en) | Treatment of Cancer | |
| Landry et al. | Biomarkers of immunotherapy response in neuro-oncology | |
| RU2812782C2 (ru) | Способ лечения острого миелоидного лейкоза | |
| JP7428717B2 (ja) | 急性骨髄性白血病の治療方法 | |
| Perdikis-Prati et al. | Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Case-Illustrated Narrative Review | |
| Alkhalili et al. | Do corticosteroids compromise survival in glioblastoma? | |
| Logun et al. | CTIM-40. EARLY RADIOGRAPHIC RESPONSE AND ENGRAFTMENT OF PHASE I FIRST-IN-HUMAN BICISTRONIC CAR T CELLS CORRELATE WITH REAL-TIME AUTOLOGOUS GBM ORGANOID CYTOLYSIS | |
| Perdikid-Prati et al. | Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Case-Illustrated Narrative | |
| US20220143016A1 (en) | Method for treating a multiple myeloma | |
| CN119818513A (zh) | 治疗儿科患者的癌症的方法 | |
| Yoosuf | Long Term Chemotherapy Treatment Induces a Dual Immune Resistance in Colorectal Cancer Cells | |
| KR20260061462A (ko) | 소아 환자의 암 치료 방법 | |
| HK40124036A (zh) | 治疗儿科患者的癌症的方法 | |
| EP3947379A1 (en) | Combinations useful in a method for treating sarcoma |